

Maija HollmÃ©n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3951976/publications.pdf>

Version: 2024-02-01

58
papers

2,402
citations

257429

24
h-index

214788

47
g-index

65
all docs

65
docs citations

65
times ranked

4320
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonclinical Characterization of Bexmarilimab, a Clever-1 Targeting Antibody for Supporting Immune Defense Against Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1207-1218.	4.1	5
2	Novel Biomarkers for Diagnosing Periprosthetic Joint Infection from Synovial Fluid and Serum. <i>JBJS Open Access</i> , 2021, 6, .	1.5	11
3	Vascular Adhesion Protein 1 Mediates Gut Microbial Flagellin-Induced Inflammation, Leukocyte Infiltration, and Hepatic Steatosis. <i>Sci</i> , 2021, 3, 13.	3.0	3
4	A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3313.	4.1	18
5	Lymphatic Endothelial Cell Activation and Dendritic Cell Transmigration Is Modified by Genetic Deletion of Clever-1. <i>Frontiers in Immunology</i> , 2021, 12, 602122.	4.8	22
6	Intravenous Interferon- γ 1a for the Treatment of Ischemia-Reperfusion Injury in Acute Myocardial Infarct in Pigs. <i>Heart Surgery Forum</i> , 2021, 24, E409-E413.	0.5	0
7	Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4205-4220.	7.0	29
8	LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types. <i>Annals of Oncology</i> , 2021, 32, S1313.	1.2	2
9	Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferation. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7851-7872.	5.4	1
10	Melanocortin 1 Receptor Deficiency in Hematopoietic Cells Promotes the Expansion of Inflammatory Leukocytes in Atherosclerotic Mice. <i>Frontiers in Immunology</i> , 2021, 12, 774013.	4.8	8
11	Red blood cell transfusion induces abnormal HIF-1 α response to cytokine storm after adult cardiac surgery. <i>Scientific Reports</i> , 2021, 11, 22230.	3.3	5
12	Metastable Atrial State Underlies the Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation. <i>Circulation</i> , 2020, 141, 301-312.	1.6	28
13	1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer. <i>Annals of Oncology</i> , 2020, 31, S706-S707.	1.2	1
14	Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. <i>Intensive Care Medicine</i> , 2020, 46, 1937-1940.	8.2	29
15	Adipose Tissue Hypertrophy, An Aberrant Biochemical Profile and Distinct Gene Expression in Lipedema. <i>Journal of Surgical Research</i> , 2020, 253, 294-303.	1.6	48
16	Interferon beta-1a for COVID-19: critical importance of the administration route. <i>Critical Care</i> , 2020, 24, 335.	5.8	35
17	New tools to prevent cancer growth and spread: a Clever TM approach. <i>British Journal of Cancer</i> , 2020, 123, 501-509.	6.4	34
18	Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology. <i>Scientific Reports</i> , 2020, 10, 10947.	3.3	34

#	ARTICLE	IF	CITATIONS
19	Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.. Journal of Clinical Oncology, 2020, 38, 3097-3097.	1.6	7
20	Ex Vivo Modelling of Therapy Efficacy for Rare Krukenberg Tumors – A Report of Two Cases. Clinical Oncology and Research, 2020, , 1-8.	0.0	1
21	Abstract 16742: Single-Cell Transcriptional and Epigenomic Dissection of Human Heart in Health and Coronary Artery Disease Reveals Cell-type-Specific Driver Genes and Pathways. Circulation, 2020, 142, .	1.6	0
22	Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils. Immunity, 2019, 51, 561-572.e5.	14.3	149
23	Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours. Annals of Oncology, 2019, 30, v865-v866.	1.2	5
24	Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunology, 2019, 4, .	11.9	13
25	Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors. Clinical Cancer Research, 2019, 25, 3289-3303.	7.0	73
26	Editorial: Targeting Myeloid Cells to Fight Cancer. Frontiers in Immunology, 2019, 10, 2835.	4.8	2
27	Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine, 2019, 114, 74-80.	3.2	7
28	Melanocortin 1 Receptor Deficiency Promotes Atherosclerosis in Apolipoprotein E ^{0/0} Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 313-323.	2.4	22
29	P1655Preoperative predictors for systemic inflammatory response in open-heart surgery. European Heart Journal, 2018, 39, .	2.2	0
30	Enhanced Antibody Production in Clever-1/Stabilin-1 Deficient Mice. Frontiers in Immunology, 2018, 9, 2257.	4.8	12
31	Six-Week Endurance Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in Over-weight Women. Frontiers in Microbiology, 2018, 9, 2323.	3.5	145
32	Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice. PLoS ONE, 2018, 13, e0198262.	2.5	22
33	Abstract 4744: Disruption of Clever-1 in macrophages activates the innate immune response and mediates tumor rejection. , 2018, , .		1
34	Abstract 4740: CLEVER-1 as a marker to identify breast cancer patients under immunosuppression. , 2018, , .		0
35	Regulation of CD73 in the development of lower limb atherosclerosis. Purinergic Signalling, 2017, 13, 127-134.	2.2	10
36	New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget, 2017, 8, 1007-1022.	1.8	22

#	ARTICLE	IF	CITATIONS
37	Compared to Intermittant Claudication Critical Limb Ischemia Is Associated with Elevated Levels of Cytokines. <i>PLoS ONE</i> , 2016, 11, e0162353.	2.5	24
38	Transcriptional profiling of macrophage and tumor cell interactions in vitro. <i>Genomics Data</i> , 2016, 8, 1-3.	1.3	5
39	Transgenic overexpression of VEGF-C induces weight gain and insulin resistance in mice. <i>Scientific Reports</i> , 2016, 6, 31566.	3.3	52
40	G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1115177.	4.6	123
41	Soluble CD73 in Critically Ill Septic Patients – Data from the Prospective FINNAKI Study. <i>PLoS ONE</i> , 2016, 11, e0164420.	2.5	7
42	Lymphatic endothelial cells attenuate inflammation via suppression of dendritic cell maturation. <i>Oncotarget</i> , 2016, 7, 39421-39435.	1.8	60
43	Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. <i>European Journal of Immunology</i> , 2015, 45, 562-573.	2.9	25
44	Pharmakokinetik von Medikamenten durch Echtzeit-Analyse der Atemluft von Mäusen. <i>Angewandte Chemie</i> , 2015, 127, 7926-7929.	2.0	2
45	Drug Pharmacokinetics Determined by Real-Time Analysis of Mouse Breath. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 7815-7818.	13.8	55
46	Aberrant Circulating Levels of Purinergic Signaling Markers Are Associated With Several Key Aspects of Peripheral Atherosclerosis and Thrombosis. <i>Circulation Research</i> , 2015, 116, 1206-1215.	4.5	42
47	Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. <i>Scientific Reports</i> , 2015, 5, 9188.	3.3	119
48	Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet. <i>Molecular Metabolism</i> , 2015, 4, 93-105.	6.5	105
49	Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis. <i>Clinical Cancer Research</i> , 2014, 20, 6452-6464.	7.0	75
50	Fingerprinting Breast Cancer vs. Normal Mammary Cells by Mass Spectrometric Analysis of Volatiles. <i>Scientific Reports</i> , 2014, 4, 5196.	3.3	20
51	The Orphan Adhesion G Protein-coupled Receptor GPR97 Regulates Migration of Lymphatic Endothelial Cells via the Small GTPases RhoA and Cdc42. <i>Journal of Biological Chemistry</i> , 2013, 288, 35736-35748.	3.4	49
52	Proteolytic Processing of ErbB4 in Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e39413.	2.5	37
53	Abstract B187: ErbB4 ectodomain as a biomarker and a potential therapeutic target for breast cancer.., 2011, , .		0
54	Potential of ErbB4 antibodies for cancer therapy. <i>Future Oncology</i> , 2010, 6, 37-53.	2.4	31

#	ARTICLE	IF	CITATIONS
55	Somatic Mutations of ErbB4. <i>Journal of Biological Chemistry</i> , 2009, 284, 5582-5591.	3.4	55
56	Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. <i>Oncogene</i> , 2009, 28, 1309-1319.	5.9	54
57	Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor. <i>Neoplasia</i> , 2009, 11, 629-IN1.	5.3	65
58	Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II α gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. <i>Annals of Oncology</i> , 2005, 16, 273-278.	1.2	585